• 23 October 2018

    The board of directors of InDex Pharmaceuticals Holding AB (publ) (the “Company” or “InDex”) has, with support from the authorization granted by the annual general meeting on May 24, 2018, resolved on a directed share issue of 6,252,842 shares to a small group of investors. The subscription price is SEK 6.02 per share, corresponding to a discount in line with market conditions of 7.7 percent to the 5-day volume weighted average price and 1.3 percent to today’s closing price. InDex will receive proceeds of approximately SEK 37.5 million after transaction related costs for legal services and costs for registration and practical management.

  • 18 October 2018

    Sonendo®, the developer of the GentleWave® System, today announced that it has acquired TDO (The Digital Office™) Software.

  • 15 October 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that an abstract with preclinical data that demonstrate the activity of GKT831, the Company’s lead product candidate, in reversing fibrosis in a MDR2 KO mouse model will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (the Liver Meeting®), which will take place in San Francisco, November 9-13, 2018. The poster will be presented on Saturday, November 10 (2:00 pm–7:30 pm; Presenters Available: 5:30 pm–7:30 pm).

  • 15 October 2018

    Sequana Medical NV (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the opening of its new corporate headquarters in Ghent, Belgium, at the epicentre of the Flanders healthcare hub, and the investment of €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders.

  • 8 October 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today the presentation of preclinical data showing that GKT831, the Company’s clinical stage NOX1 and NOX4 inhibitor, efficiently targeted cancer associated fibroblasts (CAFs) in prostate cancer and abrogated the pro-tumorigenic influence of the tumor micro-environment. The results were presented by Dr. Natalie Sampson, Division of Experimental Urology, Dept. of Urology, Medical University of Innsbruck, Austria, at ESUR18 – the 25th Meeting of the European Association of Urology, taking place October 4-6, 2018, in Athens, Greece (ESUR18, October 5, Poster #P-23).